[1] 敬媛媛,王洁,刘娜,等. 免疫性血小板输注无效患者的人类白细胞抗原/人类血小板抗原抗体分布特征及其对交叉配型效果的影响[J]. 北京医学,2022,44(2):163-167. [2] 何吉. 血小板配型及相容性输注的专家共识[J]. 浙江医学,2021,43(13):1367-1371. [3] 陈麟凤,潘继春,冯倩,等. 26045例血小板输注效果的影响因素分析研究[J]. 中国实验血液学杂志,2015,23(4): 1081-1086. [4] 谭茜茜,魏习薇,巩天祥,等. 血小板抗体筛查及交叉配型的临床应用[J]. 中国输血杂志,2021,34(4):382-385. [5] Pène F,Russell L,Aubron C.Thrombocytopenia in the intensive care unit: diagnosis and management[J]. Ann Intensive Care,2025,15(1):25. [6] 范成艳,温玉洁,张丹,等. 免疫性血小板输注无效患者HLA/HPA抗体特性分析及其对血小板输注效果的影响[J]. 临床输血与检验,2024,26(3):353-358. [7] Couvidou A,Rojas-Jiménez G,Dupuis A,et al.Anti-HLA Class I alloantibodies in platelet transfusion refractoriness: From mechanisms and determinants to therapeutic prospects[J]. Front Immunol,2023,14:1125367. [8] Youk H J,Hwang S H,Oh H B,et al.Evaluation and management of platelet transfusion refractoriness[J]. Blood Res,2022,57(S1):6-10. [9] 都新萍,宫淑文,杨青. 急性髓细胞性白血病患者血小板输注效果的影响因素分析[J]. 中国医药导报,2024,21(8): 123-126. [10] Song X F,Qi J Q,Fang K,et al.A meta-analysis of risk factors associated with platelet transfusion refractoriness[J]. Int J Hematol,2023,117(6):863-875. [11] Chen J F,Liu W W,Zhou Z H.Predictors of ineffective platelet transfusion in surgical ICU: A retrospective study[J]. Medicine,2026,105(11):e48062. [12] Zou Y,Jiang T H,Fan Y,et al.Analysis of influencing factors and predictive model construction for platelet transfusion efficacy in hematological patients[J]. Front Med,2025,12:1632042. [13] Li X H,Liu Q,Dong J J,et al.Existence and significance of anti-HLA-C autoantibodies to primary and persistent platelet transfusion refractoriness in patients with hematologic disorders: a retrospective study from a single centre[J]. Ann Med,2025,57(1):2446689. |